Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants-Reference-Cited by-同舟云学术

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants

Published:2020-12 Issue: Volume:207 Page:112744
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Wang Beilei,Zhang Wentao,Liu Xuesong,Zou Fengming,Wang Junjie,Liu Qingwang,Wang Aoli,Hu Zhenquan,Chen Yongfei,Qi Shuang,Jiang Zongru,Chen Cheng,Hu Chen,Wang Li,Wang Wenchao,Liu Qingsong,Liu Jing

Funder

National Natural Science Foundation of China

Personalized Medicines-Molecular Signature-Based Drug Discovery and Development

Strategic Priority Research Program of the Chinese Academy of Sciences

National Science & Technology Major Project

Key New Drug Creation and Manufacturing Program” of China

Natural Science Foundation of Anhui Province

China Postdoctoral Science Foundation

Postdoctoral Science Foundation of Anhui Province

Frontier Science Key Research Program of CAS

CASHIPS Director’s Fund

University Synergy Innovation Program of Anhui Province